Accedi a banche dati online | Convegnodetail
Anteprima di stampa

Head and Neck Cancer Drug Development Summit

Evvnt Promotion / evvnt
30.11.2021 - 01.12.2021  Virtual
Time: 09:00 to 15:00
Temi della conferenza
The Head and Neck Cancer Drug Development Summit has been curated with the industry in mind. Development in the head and neck cancer space has entered the most active period to date, with emerging immunotherapy biotechs, leading biopharma companies, and pioneering academics racing to exploit this immunogenic tumor, validate early clinical data from broader solid tumor trials, and improve clinical outcomes in this indication with a high unmet medical need.
Professional congress organizer (PCO)
Hanson Wade

Speakers: Lars Birgerson, Chief Executive Officer, Adlai Nortye, Sophia Randolph, Chief Medical Officer, Alexo Therapeutics Inc., Michael Needle, Chief Medical Officer, AVEO Oncology, and more.

Informazioni ed Iscrizioni:
Mr. Customer Service
Quote del Congresso
Industry Rate - Early Bird 1 Pricing (save $500): USD 1599.00, Industry Rate - Final Price: USD 2099.00, Solution Provider Rate - Early Bird 1 Pricing (save $700): USD 1899.00, Solution Provider Rate - Final Price: USD 2599.00
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Alumni Club Medizinische Universität WienAMREF - African Medical and Research FoundationÖsterreichische Akademie der ÄrzteAnästhesie in Entwicklungsländern e. V.European Public Health Association (EUPHA)Ärzte der WeltAGEM - Arbeitsgemeinschaft Ethnologie und MedizinOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation